How Transmural Healing Redefines Crohn’s Disease Care

Crohn’s disease treatment has evolved rapidly with the introduction of novel biologic therapies. Today, clinicians frequently adopt a ‘top-down’ treatment strategy. Specifically, they prescribe the most potent biologics early to alter the natural course of the disease. However, determining true therapeutic success remains highly complex. Traditional methods often rely only on endoscopic mucosal evaluation. In contrast, modern gastroenterologists now emphasize transmural healing as a superior treatment target. This shifting paradigm integrates biomarkers, symptoms, and advanced imaging to make optimal clinical decisions.

The Role of Imaging in Achieving Transmural Healing

Cross-sectional imaging provides a complete view of the entire bowel wall. Consequently, radiologists can easily identify occult inflammation that endoscopy might miss. This ability is particularly critical because mucosal healing does not guarantee complete remission. Indeed, active inflammation can persist in the deeper bowel layers despite a healthy-looking mucosa. Therefore, assessing the bowel wall through imaging offers a more reliable predictor of long-term outcomes. Furthermore, these imaging evaluations help clinicians decide when to escalate, de-escalate, or switch biological therapies.

Quantitative Methods and Motility Assessments

Standardizing these imaging reports remains vital for consistent clinical management. For this reason, researchers have developed advanced quantitative imaging methods. These techniques include contrast-enhanced ultrasound and T1 mapping at magnetic resonance imaging. Additionally, standardized stricture assessments and velocity-encoded phase-contrast imaging provide precise measurements of tissue damage. However, morphologic healing at imaging often lags behind clinical improvement. In these specific cases, evaluating changes in bowel motility can offer valuable diagnostic clues. Specifically, tracking motility can detect early therapeutic response long before the inflamed segment fully normalizes.

Collaborative Care Drives Crohn’s Disease Management

A strong partnership between the gastroenterologist and the radiologist optimizes patient care. Moreover, the radiologist identifies subclinical and endoscopically occult disease to prevent future flares. As a result, the clinical team can tailor biologic therapies to the exact needs of each patient. This collaborative approach ensures that the treatment targets deep, transmural remission. Ultimately, integrating advanced imaging into routine practice will significantly improve patient outcomes across India and the globe.

Frequently Asked Questions

Q1: Why is mucosal healing alone sometimes insufficient in Crohn’s disease?

Crohn’s disease causes transmural inflammation that affects the entire bowel wall. Consequently, healing only the inner mucosal lining may still leave active inflammation in the outer layers, which increases the long-term risk of strictures and other complications.

Q2: Which imaging techniques help standardize Crohn’s disease response assessment?

Clinicians utilize several advanced quantitative methods to track therapeutic responses. For example, contrast-enhanced ultrasound, magnetic resonance T1 mapping, standardized stricture evaluation, and velocity-encoded phase-contrast imaging provide objective data.

Q3: What should clinicians do when morphologic imaging changes lag behind clinical improvement?

In cases where physical structure changes lag behind, clinicians can evaluate bowel motility. Specifically, measuring segment motility can help identify early treatment responses before full bowel normalization occurs.

References

1. Patel RD et al. Update on Novel Biologic Therapies for Crohn Disease and the Impact of Imaging on Clinical Decision Making. Radiographics. 2026 Jun undefined. doi: 10.1148/rg.250162. PMID: 42207683.
2. Turner D et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 May;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031.
3. Castiglione F et al. One-year clinical outcomes with biologics in Crohn’s disease: transmural healing compared with mucosal or no healing. Aliment Pharmacol Ther. 2019 Apr;49(8):1026-1039. doi: 10.1111/apt.15190.